OmniAb, Inc.
OABI Nasdaq· Services-Commercial Physical & Biological Research
Last close · Oct 23, 2026
$4.66
KIRA · Stoqly’s AI analyst, in plain words
- OmniAb, Inc. had $18.7M of revenue in fiscal 2025, down 29.3% on the year before.
- Its operating margin was −369.5%, down 87.2 pts: of every 100 in sales, about −369 is left after running the business.
- OmniAb, Inc. lost $64.8M in fiscal 2025.
- Free cash flow was −$37.0M in fiscal 2025, −198.3% of revenue.
Market cap
$600M
P/E
—
Revenue
$18.7M
Net income
−$64.8M
Free cash flow
−$37.0M
Operating margin
−369.5%
OmniAb, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−29.3%
No. Sales fell 29.3% last year.
Does it make a profit?
−347.0%
No. It lost money last year.
Does profit turn into cash?
−198.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What OmniAb, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- OmniAb, Inc.
- CIK
- 0001846253
OmniAb, Inc. · OABI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $34.7M | $59.1M | $34.2M | $26.4M | $18.7M |
| Revenue growth | — | 70.0% | −42.2% | −22.8% | −29.3% |
| Operating margin | −102.5% | −45.1% | −203.2% | −282.3% | −369.5% |
| Net income | −$27.0M | −$22.3M | −$50.6M | −$62.0M | −$64.8M |
| Net margin | −77.8% | −37.8% | −148.2% | −235.1% | −347.0% |
| Diluted EPS | −$0.33 | −$0.26 | −$0.51 | −$0.61 | −$0.57 |
| Cash | |||||
| Cash from operations | −$5.7M | −$3.6M | $2.3M | −$39.7M | −$36.5M |
| Capital expenditure | $4.1M | $17.2M | $1.6M | $1.9M | $0.6M |
| Free cash flow | −$9.7M | −$20.8M | $0.7M | −$41.5M | −$37.0M |
| FCF margin | −28.0% | −35.1% | 2.1% | −157.4% | −198.3% |
| Share count change | — | 3.3% | 16.8% | 2.7% | 11.0% |
| Debt and strength | |||||
| Cash and short-term investments | $0.0M | $88.3M | $87.0M | $59.4M | $54.0M |
| Shareholders' equity | $234M | $341M | $315M | $288M | $267M |
| Current ratio | 1.1x | 4.8x | 4.1x | 4.5x | 4.0x |
| Interest coverage | −5,087.0x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −11.5% | −7.8% | −15.4% | −20.6% | −23.4% |
| Return on tangible equity | — | −24.8% | −67.4% | −94.6% | −111.9% |
| Piotroski F-score | — | 4 | 2 | 2 | 1 |
| Altman Z'' | 2.8 | 5.7 | 5.1 | 6.5 | 6.0 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.3M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
OmniAb, Inc. · OABI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.66 a share, the company is worth $600M.
Source: SEC EDGAR XBRL filings (CIK 0001846253). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.